Health
Dyadic C1 protein expression platform explored in fight against COVID-19 – Medical Plastics News
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced…
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced from Dyadics industrially proven proprietary and patented hyper-productive C1 gene expression platform.
The RBD was produced at three grams per liter (3 g/l) in only five days.
Dyadics C1 Rapid Recombinant Protein Manufacturing Platform can manufacture monoclonal antibodies (mAbs) more efficiently and faster than currently existing C…
-
General15 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News24 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News15 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News22 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime